83 related articles for article (PubMed ID: 15670841)
1. Modulation of Alzheimer's pathology by cerebro-ventricular grafting of hybridoma cells expressing antibodies against Abeta in vivo.
Gaugler MN; Tracy J; Kuhnle K; Crameri A; Nitsch RM; Mohajeri MH
FEBS Lett; 2005 Jan; 579(3):753-6. PubMed ID: 15670841
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy of Alzheimer's disease (AD): from murine models to anti-amyloid beta (Abeta) human monoclonal antibodies.
Geylis V; Steinitz M
Autoimmun Rev; 2006 Jan; 5(1):33-9. PubMed ID: 16338209
[TBL] [Abstract][Full Text] [Related]
3. Peripheral and central biodistribution of (111)In-labeled anti-beta-amyloid autoantibodies in a transgenic mouse model of Alzheimer's disease.
Bacher M; Depboylu C; Du Y; Noelker C; Oertel WH; Behr T; Henriksen G; Behe M; Dodel R
Neurosci Lett; 2009 Jan; 449(3):240-5. PubMed ID: 18786612
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy against APP beta-secretase cleavage site improves cognitive function and reduces neuroinflammation in Tg2576 mice without a significant effect on brain abeta levels.
Rakover I; Arbel M; Solomon B
Neurodegener Dis; 2007; 4(5):392-402. PubMed ID: 17536186
[TBL] [Abstract][Full Text] [Related]
5. Active immunization trial in Abeta42-injected P301L tau transgenic mice.
Kulic L; Kurosinski P; Chen F; Tracy J; Mohajeri MH; Li H; Nitsch RM; Götz J
Neurobiol Dis; 2006 Apr; 22(1):50-6. PubMed ID: 16289870
[TBL] [Abstract][Full Text] [Related]
6. Direct in vivo intracellular selection of conformation-sensitive antibody domains targeting Alzheimer's amyloid-beta oligomers.
Meli G; Visintin M; Cannistraci I; Cattaneo A
J Mol Biol; 2009 Apr; 387(3):584-606. PubMed ID: 19361429
[TBL] [Abstract][Full Text] [Related]
7. Reduction of amyloid beta-peptide accumulation in Tg2576 transgenic mice by oral vaccination.
Ishii-Katsuno R; Nakajima A; Katsuno T; Nojima J; Futai E; Sasagawa N; Yoshida T; Watanabe Y; Ishiura S
Biochem Biophys Res Commun; 2010 Sep; 399(4):593-9. PubMed ID: 20682291
[TBL] [Abstract][Full Text] [Related]
8. The underestimated potential of the immune system in prevention of Alzheimer's disease pathology.
Mohajeri MH
Bioessays; 2007 Sep; 29(9):927-32. PubMed ID: 17688240
[TBL] [Abstract][Full Text] [Related]
9. Epitope and isotype specificities of antibodies to beta -amyloid peptide for protection against Alzheimer's disease-like neuropathology.
Bard F; Barbour R; Cannon C; Carretto R; Fox M; Games D; Guido T; Hoenow K; Hu K; Johnson-Wood K; Khan K; Kholodenko D; Lee C; Lee M; Motter R; Nguyen M; Reed A; Schenk D; Tang P; Vasquez N; Seubert P; Yednock T
Proc Natl Acad Sci U S A; 2003 Feb; 100(4):2023-8. PubMed ID: 12566568
[TBL] [Abstract][Full Text] [Related]
10. Antibody capture of soluble Abeta does not reduce cortical Abeta amyloidosis in the PDAPP mouse.
Seubert P; Barbour R; Khan K; Motter R; Tang P; Kholodenko D; Kling K; Schenk D; Johnson-Wood K; Schroeter S; Gill D; Jacobsen JS; Pangalos M; Basi G; Games D
Neurodegener Dis; 2008; 5(2):65-71. PubMed ID: 18182780
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy for Alzheimer's disease.
McGeer PL; McGeer E
Sci Aging Knowledge Environ; 2004 Jul; 2004(27):pe29. PubMed ID: 15243154
[TBL] [Abstract][Full Text] [Related]
12. Reduced oligomeric and vascular amyloid-beta following immunization of TgCRND8 mice with an Alzheimer's DNA vaccine.
DaSilva KA; Brown ME; McLaurin J
Vaccine; 2009 Feb; 27(9):1365-76. PubMed ID: 19150380
[TBL] [Abstract][Full Text] [Related]
13. Novel approaches for immunotherapeutic intervention in Alzheimer's disease.
Vasilevko V; Cribbs DH
Neurochem Int; 2006 Jul; 49(2):113-26. PubMed ID: 16765487
[TBL] [Abstract][Full Text] [Related]
14. Generation of anti-beta-amyloid antibodies via phage display technology towards Alzheimer's disease vaccination.
Solomon B
Vaccine; 2005 Mar; 23(17-18):2327-30. PubMed ID: 15755621
[TBL] [Abstract][Full Text] [Related]
15. Reduced serum level of antibodies against amyloid beta peptide is associated with aging in Tg2576 mice.
Sohn JH; So JO; Kim H; Nam EJ; Ha HJ; Kim YH; Mook-Jung I
Biochem Biophys Res Commun; 2007 Sep; 361(3):800-4. PubMed ID: 17678618
[TBL] [Abstract][Full Text] [Related]
16. Globular amyloid beta-peptide oligomer - a homogenous and stable neuropathological protein in Alzheimer's disease.
Barghorn S; Nimmrich V; Striebinger A; Krantz C; Keller P; Janson B; Bahr M; Schmidt M; Bitner RS; Harlan J; Barlow E; Ebert U; Hillen H
J Neurochem; 2005 Nov; 95(3):834-47. PubMed ID: 16135089
[TBL] [Abstract][Full Text] [Related]
17. Plasma antibodies to Abeta40 and Abeta42 in patients with Alzheimer's disease and normal controls.
Xu W; Kawarabayashi T; Matsubara E; Deguchi K; Murakami T; Harigaya Y; Ikeda M; Amari M; Kuwano R; Abe K; Shoji M
Brain Res; 2008 Jul; 1219():169-79. PubMed ID: 18534566
[TBL] [Abstract][Full Text] [Related]
18. Consequence of Abeta immunization on the vasculature of human Alzheimer's disease brain.
Boche D; Zotova E; Weller RO; Love S; Neal JW; Pickering RM; Wilkinson D; Holmes C; Nicoll JA
Brain; 2008 Dec; 131(Pt 12):3299-310. PubMed ID: 18953056
[TBL] [Abstract][Full Text] [Related]
19. Abeta42 immunization in Alzheimer's disease generates Abeta N-terminal antibodies.
Lee M; Bard F; Johnson-Wood K; Lee C; Hu K; Griffith SG; Black RS; Schenk D; Seubert P
Ann Neurol; 2005 Sep; 58(3):430-5. PubMed ID: 16130106
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity and therapeutic efficacy of phage-displayed beta-amyloid epitopes.
Esposito M; Luccarini I; Cicatiello V; De Falco D; Fiorentini A; Barba P; Casamenti F; Prisco A
Mol Immunol; 2008 Feb; 45(4):1056-62. PubMed ID: 17850871
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
